Gene mutation revelation points to new target for myeloma treatment, studies say.
Garber
Ken
K
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy*; D009154:Mutation; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000235:genetics*; D011719:Pyrazines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D048008:TNF Receptor-Associated Factor 3 / Q000187:drug effects / Q000235:genetics
D000970:Antineoplastic Agents; D001897:Boronic Acids; D016328:NF-kappa B; D011719:Pyrazines; D048008:TNF Receptor-Associated Factor 3; C090656:TRAF3 protein, human; D000069286:Bortezomib; D051550:I-kappa B Kinase; C496560:IKBKB protein, human